Testing IBI3003 for relapsed or refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new drug called IBI3003 in people whose multiple myeloma (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can shrink the cancer and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with multiple myeloma that has come back or is no longer responding to prior treatment
- Your blood or urine shows measurable signs of myeloma (specific protein levels in blood or urine)
- You have a life expectancy of at least 3 months
- If you can have children, you agree to use birth control during the study and for 90 days after the last dose
- You have not previously received treatments specifically targeting BCMA or GPRC5D proteins (two specific targeted therapies)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
This trial tests a new drug called IBI3003 for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if IBI3003 is safe and effective.
This trial tests an investigational drug called IBI3003 in people with multiple myeloma that has come back or hasn't responded to previous treatments. The goal is to see if it is safe and effective.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This study tests a new treatment called TQB2934 for people with multiple myeloma that has returned or hasn't gotten better after treatment. The goal is to see if it can help control the disease.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.